Back Bay Life Science Advisors CEO Jonathan Gertler to Moderate Precision Medicine Panel Discussion with John Quackenbush and Geoffrey McDonough

Back Bay Life Science Advisors CEO Jonathan Gertler will moderate a panel discussion about corporate strategy around precision medicine at The Convergence Forum, the annual ideas exchange that brings together high-level life science leaders from around New England.

Back Bay Life Science Advisors is once again a key sponsor of Convergence, which takes place May 11-12 in Cape Cod, MA, supporting the facilitation of ideas and vision across biotech, pharmaceuticals, healthcare IT, medical devices, synthetic biology and more.

The Back Bay team brings to the forum deep industry expertise from the clinical, scientific, commercial and transactional crossroads – particularly in areas of attracting funding from new sources, life science product commercialization, lifecycle management and corporate growth strategy for life science companies.

This year, Dr. Gertler will moderate “How Should Corporate Strategy Incorporate Precision Medicine?” with Sobi CEO Geoffrey McDonough, MD, and Harvard University Professor of Computational Biology and Bioinformatics John Quackenbush, PhD. Dr. Gertler described the panel on The Bloomberg Baystate Business Hour.

Precision medicine potentially creates a new value proposition for companies, impacting many sectors of the life science industry. However, the complexity of our system – including payers, patient advocates, and providers – makes the business translation of this innovative concept challenging.

As the ability increases to identify patient segments with targeted therapeutics across different clinical verticals, companies must look for new strategies to promote innovation and serve patients. Precision medicine must be considered in evolving corporate thinking. The Convergence panel will explore how to best incorporate the burgeoning precision field into corporate planning.

Back Bay will share learnings from The Convergence Forum and thoughts on corporate strategy and precision medicine in our May newsletter.